These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10178657)

  • 1. A short term cost-effectiveness model for oral antidiabetic medicines in Europe.
    Hood SC; Annemans L; Rutten-van Mölken M
    Pharmacoeconomics; 1998 Mar; 13(3):317-26. PubMed ID: 10178657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
    Ramsdell JW; Braunstein SN; Stephens JM; Bell CF; Botteman MF; Devine ST
    Pharmacoeconomics; 2003; 21(11):819-37. PubMed ID: 12859222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A short term cost-effectiveness model for oral antidiabetic medicines in Europe.
    MacKeigan LD
    Pharmacoeconomics; 1998 Dec; 14(6):709-10. PubMed ID: 10346421
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes.
    Brown RR
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S24-7. PubMed ID: 9872692
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparison of costs for four oral antidiabetic regimens within a managed care population.
    Stockl K; Vanderplas AM; Nicklasson L
    Manag Care Interface; 2003 Jul; 16(7):31-6. PubMed ID: 12908215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
    Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
    Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Gu S; Deng J; Shi L; Mu Y; Dong H
    J Med Econ; 2015; 18(10):808-20. PubMed ID: 25950193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH; Seo SJ; Smith-Palmer J; Palmer JL; White J; Valentine WJ
    Value Health; 2009; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analyses of the conversion of patients with non-insulin-dependent diabetes mellitus from glipizide to glyburide and of the accompanying pharmacy follow-up clinic.
    Law AV; Pathak DS; Segraves AM; Weinstein CR; Arneson WH
    Clin Ther; 1995; 17(5):977-87. PubMed ID: 8595649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glyburide compared to insulin for the treatment of gestational diabetes mellitus: a cost analysis.
    Goetzl L; Wilkins I
    J Perinatol; 2002; 22(5):403-6. PubMed ID: 12082477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of outpatients with type 2 diabetes mellitus assisted by a pharmaceutical care service.
    Borges AP; Guidoni CM; Freitas Od; Pereira LR
    Arq Bras Endocrinol Metabol; 2011 Dec; 55(9):686-91. PubMed ID: 22231970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial.
    Janka HU; Högy B
    Eur J Health Econ; 2008 May; 9(2):165-70. PubMed ID: 17530309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model.
    McEwan P; Evans M; Kan H; Bergenheim K
    Diabetes Obes Metab; 2010 May; 12(5):431-6. PubMed ID: 20415691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
    Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G
    Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
    Neeser K; Lübben G; Siebert U; Schramm W
    Pharmacoeconomics; 2004; 22(5):321-41. PubMed ID: 15061682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.